Solvay Pharmaceuticals acquires Innogenetics

Solvay Group holds 84.3% of Innogenetics shares

Solvay Pharmaceuticals S.A., a subsidiary of the Solvay Group, the chemical and pharmaceutical group, today announced that it succeeded to acquire Innogenetics N.V., a Belgian-based biotechnological company, in a cash transaction valued at EUR 6.5 per share, representing EUR 200.7 million for 100% of the Innogenetics shares. The offer on Innogenetics shares ran from 12 August to 5 September 2008.

After settlement of the offer, which is expected to be on 22 September, Solvay Group will hold 84.3% of the Innogenetics shares, the participation of 9.68% which Solvay held prior to the offer included. All conditions for the offer on Innogenetics have been met.

Solvay Pharmaceuticals has decided to reopen the offer from 23 September to 14 October 2008 in order to provide the remaining Innogenetics shareholders the opportunity to participate in this transaction.

The reference shareholders of Innogenetics (Rudi Mariën, Biovest CVA, Marigest Holding SA, S.A.T.E. SA and Gengest BVBA), who jointly hold 18.48% of the shares of the company, together with other institutional shareholders, have tendered their shares to Solvay.

“We are extremely pleased with the positive response of the Innogenetics shareholders”, said Werner Cautreels, CEO of Solvay Pharmaceuticals. “The reopening of the offer will provide the possibility for the remaining Innogenetics shareholders to take advantage of our offer. In the mean time, we will expedite the closing procedure of the transaction, in order to be able to implement rapidly our dual strategy : expansion of Innogenetics’ diagnostics business and leverage of both companies’ R&D competencies to accelerate the development of Solvay’s therapeutic pipeline through the implementation of biomarker, diagnostics and eventually companion diagnostics technologies”, he added.

SOLVAY PHARMACEUTICALS S.A. is a Belgian fully-owned subsidiary of Solvay Group.

SOLVAY PHARMACEUTICALS is a research driven group of companies that constitutes the global pharmaceutical business of the Solvay Group.  The company seeks to fulfill carefully selected, unmet medical needs in the therapeutic areas of neuroscience, cardiometabolic, influenza vaccines, gastroenterology and men’s and women’s health.  Its 2007 sales were EUR 2.6 billion, and it employs more than 9,000 people worldwide. For more information, visit

SOLVAY GROUP is an international chemical and pharmaceutical Group with headquarters in Brussels.  It employs more than 28,000 people in 50 countries.  In 2007, its consolidated sales amounted to EUR 9.6 billion, generated by its three sectors of activity:  Chemicals, Plastics and Pharmaceuticals.  Solvay is listed on the NYSE Euronext stock exchange in Brussels (NYSE Euronext: SOLB.BE – Bloomberg: SOLB.BB – Reuters: SOLBt.BR). Details are available at

INNOGENETICS is an international biotechnological company that develops and markets diagnostic products to improve therapy management and patient health. Innogenetics develops and markets a wide range of diagnostic assays with a focus on molecular diagnostics and multiparameter testing. Its products are sold in over 90 countries through its 6 subsidiaries and a large number of distributors. In 2007, Diagnostics sales totalled EUR 47 million, more than 95% of which were achieved outside Belgium. Founded in 1985, Innogenetics is listed on NYSE Euronext Brussels.




Leave a comment

Your email address will not be published. Required fields are marked *